Evidence map›Paper›PMID 41677375›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Ascites circRNA ASCOR Drives Platinum Resistance of High-Grade Serous Ovarian Cancer by Facilitating RPA1 Nuclear Translocation.

Hanyuan Liu, Chenchen Zhu, Xuelin Yao, Yi Liu, Jing Zhu, Yuebo Li, Hanjie Xu, Cheng Peng, Ge Shan, Liang Chen and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hanyuan LiuDepartment of Obstetrics and Gynecology, Core Facility Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Chenchen ZhuDepartment of Obstetrics and Gynecology, Core Facility Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Xuelin YaoDepartment of Endocrinology, Laboratory of Diabetes, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Yi LiuDepartment of Obstetrics and Gynecology, Core Facility Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Jing ZhuDepartment of Obstetrics and Gynecology, Core Facility Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Yuebo LiDepartment of Obstetrics and Gynecology, Core Facility Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Hanjie XuDepartment of Obstetrics and Gynecology, Core Facility Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Cheng PengDepartment of Obstetrics and Gynecology, Core Facility Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Ge ShanDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, The RNA Institute, School of Basic Medical Sciences, Center For Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, China.
Liang ChenDepartment of Cardiology, The First Affiliated Hospital of USTC, Anhui Institute of Cardiovascular Diseases, The RNA Institute, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Ying ZhouDepartment of Obstetrics and Gynecology, Core Facility Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.ORCID https://orcid.org/0000-0001-8992-7897

Funding

Anhui Provincial Key Research and Development Projects 2022e07020013Anhui Universities Outstanding Youth Research Project 2024AH020017Fundamental Research Funds for the Central Universities WK9100000050National Natural Science Foundation of China 32270590National Natural Science Foundation of China 82172773National Natural Science Foundation of China 82473382National Natural Science Foundation of China 82503869National Natural Science Foundation of China U23A20164Noncommunicable Chronic Diseases-National Science and Technology Major Project 2025ZD0545600Open Project of State Key Laboratory of Systems Medicine for Cancer KF2402-93Research Funds of Center for Advanced Interdisciplinary Science and Biomedicine of IHM QYZD20230012Research Funds of Centre for Leading Medicine and Advanced Technologies of IHM 2025IHM01010USTC Research Funds of the Double First-Class Initiative YD9100002049USTC Research Funds of the Double First-Class Initiative YD9110002021USTC Research Funds of the Double First-Class Initiative YD9110002100USTC Research Funds of the Double First-Class Initiative YD9110002101
6 · The paper itself

Abstract

High-grade serous ovarian carcinoma (HGSOC) remains the most lethal gynecologic malignancy, with platinum resistance posing the major therapeutic barrier. Malignant ascites, a hallmark of advanced HGSOC, correlates with chemoresistance and poor prognosis, yet the contribution of ascites circRNAs in this process remains obscure. Here, we identify ASCOR, a circRNA upregulated in ascites small extracellular vesicles (sEVs) from platinum-resistant HGSOC patients, predicts poor survival. ASCOR promotes platinum resistance in vitro and in vivo by enhancing cell viability, reducing apoptosis, and alleviating DNA damage, with effects also transferred via sEVs. Mechanistically, ASCOR binds RPA1 and facilitates its NUP153-dependent nuclear translocation, which recruits the RNA helicase DDX18, suppressing R-loop formation. Meanwhile, the ASCOR-RPA1-DDX18 axis activates PI3K/Akt signaling to promote platinum resistance. Targeting ASCOR with antisense oligonucleotides reverses chemoresistance in mouse models. Our study unveils an ascites circRNA-driven pathway underlying platinum resistance in HGSOC, suggesting targeting ASCOR is a promising strategy for HGSOC treatment.

Indexed as

AscitesCystadenocarcinoma, SerousDrug Resistance, NeoplasmOvarian NeoplasmsPlatinumRNA, CircularAnimalsCell Line, TumorFemaleHumansMicePlatinumRNA, CircularascitescircRNAnuclear translocationovarian cancerplatinum resistance

Identifiers

PMID41677375
PMCPMC13104110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.